US Capitol Capsule: Sequester threatens FDASIA success, Woodcock says
This article was originally published in Scrip
A hearing on 15 November of the House Energy and Commerce Health Subcommittee was not only an opportunity for the heads of the FDA's drug and device centers to brag on the progress the agency has made in implementing the Food and Drug Administration Safety and Innovation Act (FDASIA), but it also gave lawmakers a forum at which to crow about one of the few accomplishments they've made in the past year in the current rancorous Washington environment.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.